For the first quarter of the fiscal year ending March 2027, consolidated net sales were 170 million yen, operating loss was 285 million yen, ordinary loss was 287 million yen, and net loss attributable to owners of the parent was 288 million yen. Losses expanded due to increased R&D and clinical development expenses. There is no forecast for the full-year results at this time. Cash and deposits amounted to 2,326 million yen, with no material uncertainty regarding the continuity of the company.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4564","jir_company_name":"OncoCyte Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4564-20260807-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, consolidated net sales were 170 million yen, operating loss was 285 million yen, ordinary loss was 287 million yen, and net loss attributable to owners of the parent was 288 million yen. Losses expanded due to increased R&D and clinical development expenses. There is no forecast for the full-year results at this time. Cash and deposits amounted to 2,326 million yen, with no material uncertainty regarding the continuity of the company.","jir_summary":"### Overview of Operating Results\nConsolidated earnings for the first quarter of the current fiscal year totaled 170 million yen in revenue, down from the previous fiscal year. This primarily reflects costs related to foundational and drug discovery research for pharmaceutical candidates, as well as clinical development expenses for small-molecule drugs, cancer peptide vaccines, and antibody medicines. Consolidated operating loss was 285 million yen, ordinary loss 287 million yen, and net loss attributable to owners of the parent was 288 million yen. By segment, pharmaceutical R&D-related operations recorded an operating loss of 160 million yen, and cancer precision medicine-related operations recorded an operating loss of 17 million yen. The full-year FY2027 earnings guidance will be announced as soon as it is determined; no guidance has been disclosed at this time.\n\n### Financial Position and Cash Position\nAs of the end of the first quarter, total assets were 2,612 million yen, net assets 2,348 million yen. Cash and deposits were 2,326 million yen, comprising the majority of current assets. Total liabilities amounted to 264 million yen, with current liabilities of 217 million yen and long-term liabilities of 47 million yen. There are no material uncertainties regarding the continuity of the company, but note the business model involves substantial R&D expenditures.","jir_financial_highlights":"Net sales: 170\u767e\u4e07\u5186 (YoY \u25b315.2\uff05)\nOperating loss: \u25b3285\u767e\u4e07\u5186 (YoY \u25b33.)\nOrdinary loss: \u25b3287\u767e\u4e07\u5186 (YoY \u4e0d\u660e)\nNet loss attributable to owners of the parent: \u25b3288\u767e\u4e07\u5186 (YoY \u4e0d\u660e)\nCash and deposits: 2,326\u767e\u4e07\u5186 (\u524d\u671f\u672b\u6bd4 \u5897\u52a0)\nTotal issued shares: 408,243,700\u682a (\u524d\u671f\u672b\u6bd4 \u5897\u52a0)","jir_category":"","jir_hashtags":"#OncoCyte Science, #Earnings, #CancerPharmaceuticalsDiscovery, #R&DExpenditure, #ClinicalDevelopment","jir_key_figures":"Net sales: 170\u767e\u4e07\u5186\uff08YoY \u25b315.2\uff05\uff09\nOperating loss: \u25b3285\u767e\u4e07\u5186\nOrdinary loss: \u25b3287\u767e\u4e07\u5186\nNet loss attributable to owners of the parent: \u25b3288\u767e\u4e07\u5186\nCash and deposits: 2,326\u767e\u4e07\u5186","jir_meta_title":"OncoCyte Science Q1 FY2027 Earnings\uff5cSales 170 million yen, Losses Widen","jir_meta_description":"Highlights from OncoCyte Science's Q1 FY2027 earnings summary. Net sales 170 million yen, operating loss 285 million yen, net loss 288 million yen. Increases in R&D costs and progression of clinical development are the main factors.","jir_og_title":"OncoCyte Science Q1 Earnings\uff5c170 million yen","jir_og_description":"OncoCyte Science's Q1 earnings show net sales of 170 million yen, operating loss of 285 million yen, and net loss of 288 million yen. Increased R&D costs are a factor.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59269,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-99851","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n